Genensel Presents Clinical Status of COVID-19 and Shingles Treatments at 'BIX 2022'

Signed Business Agreement with Chinese Technology Consulting Company

Zynexel is giving a presentation on the Open Innovation Stage at "BioPlus-InterPhex Korea 2022," held on the 3rd at COEX in Seoul.

[Asia Economy Reporter Lee Gwanju] Genencell introduced its antiviral drugs currently under development and signed a memorandum of understanding (MOU) on the supply and export of pharmaceutical raw materials with a Chinese technology consulting company at 'BioPlus-InterPhex Korea 2022 (BIX 2022),' which opened on the 3rd.

On the same day, Genencell participated in the 'Korea-China Life and Health Industry Cooperation Association,' hosted by the Investment Promotion Office of the Chinese Ministry of Commerce, as part of the 'Open Innovation Stage' program, a session of BIX.

At the event, Genencell presented the research background and clinical status of its COVID-19 treatment and shingles treatment drugs under development. Professor Kang Se-chan of Kyung Hee University’s College of Life Sciences (Dean of the Institute of Biotechnology), who also serves as Chairman of Genencell’s Technology Management Committee, emphasized, "We are developing antiviral drug candidates based on new natural material substances and are currently conducting clinical trials. We will establish mutual cooperation with the Chinese government and companies regarding the commercialization of these pharmaceuticals and other functional substances under research."

‘ES16001,’ developed by Genencell, is a new drug candidate based on a new material extracted from the leaves of the native Korean plant Dambalsu. Supported by the Ministry of Agriculture, Food and Rural Affairs, Genencell and Kyung Hee University’s College of Life Sciences jointly developed it. ‘ES16001’ is currently undergoing global Phase 2 and 3 clinical trials as a COVID-19 treatment and domestic Phase 2a clinical trials for the shingles indication.

Additionally, Genencell signed an agreement with the Chinese science and technology consulting company 'Beijing Boyi Dasi Chao Science and Technology Development Co., Ltd. (北京博?大思潮科技?展有限公司)' regarding the supply and export of pharmaceutical raw materials and various functional raw materials, as well as technology transfer. The two companies have been exchanging under the recommendation of the Chinese Ministry of Commerce, and through this agreement, they will cooperate on securing natural material sources and commercialization in the Chinese-speaking market.

BIX 2022, where the latest trends in the bioindustry can be seen at a glance, is being held for three days until the 5th at COEX in Seoul. On the second day, the 4th, sessions on contract development and manufacturing organization (CDMO) business expansion strategies are scheduled, and on the last day, various sessions including gene-editing technology will take place.

This content was produced with the assistance of AI translation services.